Within this work, we describe the design and synthesis of a range of novel chromanones and quinolinones, based on natural products reported to possess anti-leishmanial action. The core heterocycles were obtained either via classical or ionic liquid mediated Kabbe condensation in the case of chromanones, or aqueous Sonogashira based alkynylation followed by acid-catalysed cyclisation in the case of quinolinones. Upon testing in promastigotes, axenic amastigotes and Leishmania-infected macrophages, compound 13c was identified as displaying interesting activity, inhibiting axenic amastigotes and intracellular amastigotes with IC 50 s of 25.3 and 24.6μM respectively.
Introduction
Leishmaniasis is a group of diseases caused by protozoa of the genus Leishmania, transmitted through the bite of infected sandflies. Various clinical presentations exist, notably visceral, cutaneous, and mucosal forms, with visceral disease carrying the most serious consequences. Although treatments exist, they are often toxic, expensive, or both; thus the development of novel therapies remains an important strategy [1] . One approach is to investigate the composition and activity of natural medicines used by cultures in areas of disease endemicity. Diverse natural products have been shown to exhibit anti-leishmanial activity, with much interest focussed on small oxygenated heterocycles. Several examples of these metabolites have been isolated from species used by indigenous peoples in ethnomedicine ( Figure 1 ). For example, the chromene encecalol angelate 1 was isolated from Ageratum conyzoides, a plant traditionally used for parasitic infections [2] . Upon isolation and testing, this compound showed weak activity, including an IC 50 of 14.6 μg/mL against axenic amastigotes of L. donovani. Within the genus Calea, several species have been investigated for anti-parasitic properties [3] . Among the bioactive constituents isolated from this genus are various oxygenated heterocycles including flavonoids, chromenes and chromanones. Of these, we were most interested in the chromanones known as uniflorols A and B (2) (3) , first isolated from the underground organs of Calea uniflora. An E/Z mixture of uniflorols inhibited L. major promastigote growth by 55-89% between 25-100 μg/mL, making them of interest as potential lead compounds [4] . Among other related structures, the biosynthetic precursors of oxygenated heterocycles, namely the chalcones, are well established as having diverse pharmacological potential, including as anti-leishmanial agents [5] . Both natural products, such as the licorice licochalcones, and their synthetic derivatives have been widely explored. Although biologically active, non-specificity of chalcones is often cited as a drawback of these compounds, which has been ascribed to their reactive α,β-unsaturated chalcone system [6] .
Despite this, the pleiotropic effects of these compounds attract much research interest. In addition, the potentially problematic α,β-unsaturation may not actually be a pre-requisite for activity, as evidenced by retention of bioactivity in some dihydrochalcones. These include the chromene derivatives 4-6, isolated from Crotalaria ramosissima [7] . Other natural products containing α,β-unsaturation also display interesting anti-leishmanial activity. One such example is the alkaloid piperine 7, which displays concentration-dependent inhibition of L. donovani [8] .
Taking inspiration from natural product lead structures, several groups have developed analogues of such compounds (Figure 2 ). Drawing on the observed activity of the chromene glyasperin from Smirnovia iranica, Alizadeh et al prepared twelve chromenes, some of which, notably 8, were moderately active against L. major [9] . Brenzan et al, in studying the structure activity relationships of coumarins ((-) mammea A/BB) isolated from Calophyllum brasiliense, prepared a series of analogues, of which the most active was chromanone 9, inhibiting promastigote forms of L. amazonensis with an IC 50 of 0.9μM and a CC 50 of 85.4μM in macrophages [10] . Monzote et al prepared a number of synthetic chromanols, and some of these inhibited the growth of Leishmania. The observed activity of compounds 10a-b, essentially vitamin E derivatives, was considered to be at least partly due to cyt bc(1) inhibition, in addition to antioxidative properties [11] . Notably however, in these latter two studies, activity was more prominent in 2-chromanones rather than in 4-chromanones. The importance of a chromene or chromanone system for anti-leishmanial activity in several natural products was underlined by the work of Sandjo et al, who tested a series of six natural products alone and in combination and found that the presence of these intact ring systems enhanced activity compared to their ring-opened analogues [12] . Chroman-4-one analogues of flavonols have also been evaluated against L. major, with 11 showing binding to the enzyme LmPTR1 and weak (31% at 50μM) inhibition of L. infantum [13] . Considering piperine as a lead compound, both the natural product and its analogues displayed toxicity to both L. donovani and L. amazonensis [14, 15] . This effect has been ascribed to alteration of parasite mitochondrial structure and function.
Interested in probing the structural requirements of 2-3 for antileishmanial activity, we designed three distinct target types 12-14, as shown in Figure 3 . Firstly, we envisaged 12 as more accessible, desmethyl analogues of uniflorols; 12a representing the direct analogue of the natural product and 12b-c constituting hybrid structures incorporating a lipophilic fragment. Knowing that encecalol angelate is unstable, and recognising similar potential within the uniflorols, we proposed to replace the labile ester in 12 with a more stable amine or amide functionality, with 13a and 13b the amide analogues of 12a and 12c, and 13c featuring a linear alkyl fragment. Additionally, substitution of the heterocyclic oxygen for nitrogen was considered, to investigate the effect of additional H-bond donating capability and of altering the expected logP of the molecule, as depicted in 14 (and its analogues).
Results

Chemistry
Our synthetic approach towards compounds 12 is outlined in Scheme 1. Friedel-Crafts acylation of cresol 15 with acyl chloride in neat TfOH afforded the o-hydroxy acetophenone 16 [16] . Cyclisation to afford the chromanone core was accomplished using ionic liquid-promoted Kabbe condensation, which produced the desired product 17 in significantly higher yield than under standard conditions [17] . Oxidation of 17 with persulfate afforded 18, lactarochromal, a known natural product [18] . Chemoselective bioreduction of 18 was achieved in excellent yield employing D. carota [19] with no evidence of diol formation, which occurred when we used other reportedly selective reduction protocols of ketoaldehydes, such as Na 2 CO 3 /NaBH 4 [20] or SnCl 2 /NaBH 4 [21] . This reaction represents a route to the natural product 6-hydroxymethyl-2, 2-dimethylchroman-4-one 19, previously reported from submerged cultures of a Stereum sp. [22] .
Prior to esterification to afford 12a, we were required to prepare a usable C5 synthon as the acid fragment. This is depicted in Scheme 2.
Baylis-Hillman reaction of methyl acrylate 22 with acetaldehyde, using 1,4-diazabicyclo-[2.2.2]octane (DABCO) as catalyst, provided the desired methyl 3-hydroxyl-2-methylenebutanoate 23 [23] . Reaction of 23 with N-bromosuccinimide/dimethylsulfide (NBS/Me 2 S) [23] afforded 24; alternatively, this transformation can be achieved using LiBr/H 2 SO 4 in acetonitrile at room temperature [24] , affording Z-24 in similar yield in our hands. Reaction of 24 with sodium acetate in refluxing methanol [23] followed by K 2 CO 3 -mediated ester hydrolysis produced (2E)-2-(hydroxymethyl)-2-butenoate 25. Methyl ester hydrolysis of 25 was expected to afford the free acid; however this reaction was unsatisfactory, affording only small quantities of the acid using either LiOH or Ba(OH) 2 , and with dimerization as the primary reaction. In any case, attempted direct esterification of the free acid with alcohol 19 failed. We therefore protected the primary alcohol of 25 via tetrahydropyranylation catalysed by pyridinium p-toluenesulfonate [25] . Finally, LiOH-mediated hydrolysis of the protected 26 afforded 27 in good yield. Prior to utilisation of valuable acid synthon 27, we attempted to establish suitable conditions for reaction of the related commercial acrylic acid 3,3-dimethylacrylic acid with alcohol 19. Using either ZrOCl 2 .8H 2 O [26] or tosyl chloride/N-methylimidazole [27] resulted in no reaction. Interestingly, use of pentafluorophenylammonium triflate (PFPAT) in toluene [28] with various acrylic acids resulted in isolation of 21 in quantitative yield; this compound is novel to the literature. While the use of the inexpensive coupling reagent DCC under 4-dimethylaminopyridine (DMAP) catalysis resulted in approximately 10% of ester as estimated by NMR, it proved impossible to eliminate residual DCC contamination, despite careful chromatography. However, using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) with DMAP catalysis under basic conditions afforded 20a in acceptable yield. After analogous esterification of 19 with 27 to afford 20b, deprotection of 20b was accomplished using p-toluenesulfonic acid at room temperature, yielding 12a. Compound 12b was prepared analogously to 20a via esterification of 19 with styrylacetic acid, while 12c was prepared via bromination of 17 [29] and esterification with piperic acid.
Synthesis of compound 13a is depicted in Scheme 3. Esterification of p-cyanophenol 28 followed by Fries rearrangement produced acetophenone 30. Kabbe cyclisation under standard conditions afforded the known chromanone 31. Reduction of the nitrile group was accomplished using nickel(II)/NaBH 4 [30] in the presence of di-tert-butyl dicarbonate; this reaction also reduced the benzylic ketone which was selectively re-oxidised using Jones reagent to afford the BOC-protected ketone 32. Following carbamate cleavage with trifluoroacetic acid, EDC coupling was used to afford amide 33. Removal of the tetrahydropyranyl group afforded 13a. Compound 13b was prepared analogously to 33 via amidation with piperic acid. 13c, a secondary amine, was prepared by bromination of 17 followed by coupling with octylamine.
To produce quinolinone analogues (14a-g), an alternative strategy was adopted (Scheme 4). Iodination of cyanoaniline 34 afforded 35, which was acetylated prior to Sonogashira coupling under aqueous conditions to afford alkyne 37 [31] . Acid-mediated cyclisation gave quinolinone 38, whose nitrile group was reduced analogously to that of 31, and similarly, any over-reduced alcohol could be selectively oxidised to 39 using Jones reagent. Following carbamate hydrolysis of 39, amidation with various acids was facilitated by EDC to give 14a-f. Compound 14g was obtained via terminal deprotection of 14a.
Pharmacological activity
Selected compounds were evaluated for their leishmanicidal ability against Leishmania infantum infected macrophages (Table 1 ) and also against promastigote or axenic stages of different Leishmania species (Table 2 ). In addition, compounds were tested for their cytotoxicity against bone marrow-derived macrophages (BMDM) ( Table 1 ). Treatment was performed for 24h and results obtained through evaluation of cell viability upon treatment when compared to control.
Discussion
Our target compounds were designed based on reported activity of uniflorols A and B and related structures against Leishmania, with the intent of improving activity through functional group variation and hybridisation, while improving likely pharmacokinetic behaviour. Based on the results of screening, we identified compound 13c, a secondary amine derivative, as displaying interesting activity. IC 50 s recorded for all tested compounds against intracellular amastigotes exceeded 5μM, with 12, 13, 21 and 14g having lower IC 50 s than quinolinones 14b-f. Introduction of the nitrogenated quinolinone heterocycle did not enhance activity, which may point towards a chroman or chromanone pharmacophore as optimal. None of the tested compounds showed gross toxicity towards uninfected macrophages, with 13c displaying some cytotoxicity and a selectivity index of 1.6. Only compound 14e, the styryl derivative, showed any indicative activity against L. amazonensis promastigotes. This result in itself is interesting however, as Harel et al synthesised chromane and chromene derivatives of another bioactive natural product, encecalin, and highlighted several chromane derived amines and amides as novel lead compounds, finding greater activity among the amines, and in particular, a phenylbutylamine derivative showed potent antileishmanial activity [32] . Our chromanones share some similarity with these structures but, in addition to the differential oxidation state of the heterocycle, they also lack hydroxyl or methoxyl substitution at C7. Whether our compounds may be further optimised to improve activity is the subject of ongoing work. It may well be that increased hydrophobicity may be important, as evidenced by the impact of isoprenyl and phenyl substituents in molecules such as 9, shown to display significantly greater activity than a synthetic coumarin lacking these functionalities [10] . To this end, variation of the α,β unsaturated side chain of the compounds 12 and 13 may yield derivatives of interest. We are particularly interested in pursuing compounds without the α,β unsaturated Michael acceptor functionality found within many of these natural product analogues, and in this regard are encouraged by the activity of 14e and 13c, which lack this functionality.
Conclusion
In this paper, we have demonstrated a novel synthetic route towards ester and amide derivatives of the natural chromanones uniflorol A and B, and also a parallel route towards quinolinone analogues. We also demonstrate a synthetic approach to the natural product 6-hydroxymethyl-2,2-dimethylchroman-4-one. These synthetic pathways allows access to a range of compounds, some of which show potential as antileishmanial targets.
Experimental
Chemistry
All required chemicals, solvents, and reagents were purchased from Sigma-Aldrich and were of reagent grade. Reaction progress was monitored on pre-coated thin layer chromatographic aluminum sheets (Silica Gel Merck 60 F 254 ), and TLC visualization was done using a UV lamp. Fourier transform infrared spectra were carried out with neat film coated samples on diamond using a Nicolet™ iS™ 10 FT-IR spectrophotometer (Thermo Fisher). Significant absorption peak (νmax) values are given in cm À1 . 1 H and 13 C NMR spectra were recorded on Bruker Avance 400 spectrometer at 400MHz and 100MHz, respectively, in CDCl 3 and CD 3 OD using tetramethylsilane (TMS) as the internal standard. Chemical shift values are given on the δ (ppm) scale, with signals are described as follows: s (singlet), d (doublet), dd (double doublet), t (triplet), q (quartet), br. (broad signal), m (multiplet), with coupling constants (J) expressed in Hz. Mass spectral analyses were recorded using a Waters LCT Premiere XE (ESI-TOF MS) instrument. All calculated exact mono isotopic mass distributions were calibrated against internal reference standards. 
The compound was prepared and characterized as previously described in Ref. [16] . Yield: 50%.
2,2,6-trimethylchroman-4-one (17) A mixture of 16 (3.68g; 24.5mmol), acetone (3.6mL, 49.0mmol), and morpholine (1.1mL, 12.6mmol) was added to 5g of the ionic liquid[bbim]Br [33] , and stirred at 95-100 C for 8 h. The reaction mixture was then extracted with EtOAc (3 Â 10mL). The combined EtOAc extracts were concentrated in vacuo and the resulting product was purified by flash column chromatography to yield 17, in accordance with literature data for the compound [18] (2.21g, 47%).
2,2-dimethyl-4-oxochromane-6-carbaldehyde (18) The compound was prepared and characterized as previously described in Ref. [18] . Yield: 47%.
6-(hydroxymethyl)-2,2-dimethylchroman-4-one (19) To 18 (100mg, 0.49mmol) in distilled water (50mL) was added freshly cut slices of D. carota (10g). The resulting mixture was stirred vigorously at room temperature for 72h. The reaction was filtered, and the filtrate washed with ethyl acetate (50mL). The water/ethyl acetate mixture was separated, and the ethyl acetate extract dried over Na 2 SO 4 . The crude orange oil was purified by flash column chromatography to afford the benzylic alcohol 19, in accordance with literature data for the compound [22] (76mg, 75%).
(2,2-dimethyl-4-oxochroman-6-yl)methyl 3-methylbut-2-enoate (20a) To a solution of 3,3-dimethylacrylic acid (100mg, 1.0mmol) in dichloromethane (10mL) was added EDC HCl (327mg, 1.71mmol) and DMAP (5mg). To this solution was added 19 (206mg, 1.0mmol). The reaction was stirred for 1 week at room temperature. The residual solvent was removed in vacuo, and the crude residue purified by flash column chromatography to afford ester 20a as a colourless oil (125mg, 43%). 1 13 (2,2-dimethyl-4-oxochroman-6-yl)methyl (E)-2-(hydroxyme thyl)but-2-enoate (12a) p-Toluenesulfonic acid monohydrate (5mg, 0.026mmol) was added to a solution of 20b (10mg, 0.026mmol, and MeOH (5mL) at room temperature. This solution was maintained for 24 h at room temperature, quenched with saturated aqueous NaHCO 3 (10mL), and then concentrated. The resulting mixture was extracted with EtOAc (2 Â 10mL). The combined organic extracts were washed with brine (10mL), dried over Na 2 SO 4 [1, 3] dioxol-5-yl)penta-2,4-dienoate (12c) Piperic acid (100mg, 0.46mmol) was dissolved in DMF (3mL) and K 2 CO 3 (70mg, 0.51mmol) was added. The mixture was stirred at room temperature for 30 min. The bromide of 17 [25] (140mg, 0.52mmol) was added and the mixture was stirred at 80 C for 8h, protected from light. Upon completion, the reaction was quenched with water (25mL) and extracted with dichloromethane (3 Â 10mL) and dried (Na 2 SO 4 ). The solvent was removed in vacuo, and the residue purified by flash chromatography to give 12c as a methyl 3-hydroxy-2-methylenebutanoate (23) The compound was prepared and characterized as previously described in Ref. [23] . Yield: 45%.
methyl (Z)-2-(bromomethyl)but-2-enoate (24) The compound was prepared and characterized as previously described in Ref. [23] . Yield: 79%.
methyl (E)-2-(hydroxymethyl)but-2-enoate (25) The compound was prepared and characterized as previously described in Ref. [23] . Yield: 77%.
methyl (E)-2-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)but-2enoate (26) To a solution of 25 (0.24g, 1.85mmol) in DCM (10mL) was added 3,4-dihydropyran (0.47g, 5.60mmol) and a few crystals of pyridine p-toluenesulfonate. The reaction was allowed to stir at room temperature for 72 h, after which time the reaction was partitioned between saturated sodium bicarbonate/ethyl acetate, the organic solvent evaporated, and the crude residue purified by flash chromatography to yield (29) The compound was prepared and characterized as previously described in Ref. [34] . Yield: 100%.
4-cyanophenyl acetate
3-acetyl-4-hydroxybenzonitrile (30) The compound was prepared and characterized as previously described in Ref. [34] . Yield: 55%.
2,2-dimethyl-4-oxochromane-6-carbonitrile (31) To a solution of 30 (2.74g, 17.0mmol) in toluene (30mL) was added pyrrolidine (0.5mL, 5.99mmol) and acetone (1.7mL, 23.2mmol). The resulting solution was stirred at 90 C for 3 h in a Dean Stark apparatus and then cooled. The cold mixture was evaporated in vacuo, and the residue purified by flash column chromatography to afford 31, as an off-white solid, in accordance with literature data for the compound [35] (1.95g, 57%) .
tert-butyl ((2,2-dimethyl-4-oxochroman-6-yl)methyl)carbamate (32) To a stirred solution of 31 (1.58g, 7.86mmol) in dry methanol (30mL) at 0 C and under N 2 , were added Boc 2 O (3.43g, 15.7mmol) and NiCl 2 ⋅6H 2 O (190mg, 0.80mmol). NaBH 4 (2.08g, 55.0mmol) was then added in small portions over 20min. The reaction was exothermic and effervescent. The resulting reaction mixture containing a finely divided black precipitate was allowed to warm to room temperature and left to stir for 15hr, at which point diethylenetriamine (0.75mL, 6.94mmol) was added. The mixture was allowed to stir for 30 min before solvent evaporation. The purple residue was dissolved in EtOAc (50mL) and extracted with saturated NaHCO 3 (2 Â 50mL). The organic layer was dried (Na 2 SO 4 ) and the solvent removed in vacuo to yield a mixture of products, with upon purification by flash column chromatography afforded as the predominant product the carbamate alcohol: 1 To a stirred solution of this alcohol (0.5g, mmol) in acetone (30mL) at 0 C, was added the Jones reagent (2mL). The resulting reaction was allowed to warm to room temperature and left to stir for 2hr. On appearance of the green Cr 2 (SO 4 ) 3 , anhydrous sodium sulphate (0.30g, 2.12mmol) was added. After 2 h, the solvent was evaporated, and the reaction separated using ether/water. After three washings with ether (3 Â 20mL), the combined organic extracts were filtered and the solvent removed in vacuo. (E)-N-((2,2-dimethyl-4-oxochroman-6-yl)methyl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)but-2-enamide (33) To a solution of 32 (542mg, 1.78mmol) in DCM (5ml) at 0 C was added trifluoroacetic acid (5mL). The reaction was stirred overnight, allowing the reaction to reach room temperature. When TLC analysis showed completion of the reaction, the solvent was removed in vacuo, removing any remaining TFA azeotropically. After washing with base, extracting with ether and removing the solvent gave the free amine, a dark oil, which was reacted without further purification: 0.05g, 0.24mmol of this amine was added to a solution of 27 (50mg, 0.25mmol) in dichloromethane (10mL) at 0 C containing EDC HCl (0.07g, 0.37mmol) and triethylamine (0.046mL, 0.33mmol). The reaction was allowed to reach room temperature and stirred for 24 h under a N 2 atmosphere. The residual solvent was removed in vacuo, and the crude residue purified by flash column chromatography to afford amide 33 as a colourless oil (45mg, 38% (E)-N-((2,2-dimethyl-4-oxochroman-6-yl)methyl)-2-(hydroxymethyl)but-2-enamide (13a) p-Toluenesulfonic acid monohydrate (5mg, 0.026mmol) was added to a solution of 33 (10mg, 0.026mmol, and MeOH (5mL) at room temperature. This solution was maintained for 7h at room temperature, quenched with saturated aqueous NaHCO 3 (10 mL), and then concentrated. The resulting mixture was extracted with EtOAc (2 Â 10mL). The combined organic extracts were washed with brine (10mL), dried over Na 2 SO 4 2,2-dimethyl-6-((octylamino)methyl)chroman-4-one (13c) 100mg (0.37mmol) of 6-(bromomethyl)-2,2-dimethylchroman-4-one [25] was dissolved in acetonitrile (25mL) under aerobic conditions. To this stirred solution was added octylamine (45mg, 0.35mmol), and the reaction mixture was stirred at 100 C for 4h. Upon completion, the solvent was removed in vacuo, and the residue purified by flash chromatography to give 13c as a pale golden oil (32mg, 27% (35) The compound was prepared and characterized as previously described in Ref. [36] .
N-(4-cyano-2-iodophenyl)acetamide (36) The compound was prepared and characterized as previously described in Ref. [36] .
N-(4-cyano-2-(3-hydroxy-3-methylbut-1-yn-1-yl)phenyl)acetamide (37) To 5g (17.5mmol) of 36 were added water (25mL), PdCl 2 (30mg, 1mol%) and pyrrolidine (7.3mL, 87.5mmol) under aerobic conditions. The resulting mixture was stirred at 50 C for 5 min. To this mixture was added 2-methylbut-3-yn-2-ol (1.7mL, 21mmol), and the reaction mixture was stirred at 110 C for 5h. The reaction was then extracted with EtOAc (3 Â 10 mL), and the combined organic layers dried with anhydrous sodium sulfate. The solvent was removed in vacuo to give a crude residue, which was reacted as such in the next step. IR ν max (neat) 1454, 1508, 1614, 2217, 2876, 2978, 3341cm À1 ; 1 tert-butyl ((2,2-dimethyl-4-oxo-1,2,3,4-tetrahydroquinolin-6-yl) methyl)carbamate (39) To a stirred solution of 38 (0.5g, 2.5mmol) in dry methanol (20mL) at 0 C, were added Boc 2 O (0.6g, 2.75mmol) and NiCl 2 ⋅6H 2 O (0.06g, 0.25mmol). NaBH 4 (0.47g, 12.4mmol) was then added in small portions over 10 min. The reaction was exothermic and effervescent. The resulting reaction mixture containing a finely divided black precipitate was allowed to warm to room temperature and left to stir for 15hr, at which point diethylenetriamine (0.26mL, 2.4mmol) was added. The mixture was allowed to stir for 30 min before solvent evaporation. The purple residue was dissolved in EtOAc (50mL) and extracted with saturated NaHCO 3 (2 Â 50mL). The organic layer was dried (Na 2 SO 4 ) and the solvent removed in vacuo to yield a mixture of products, including carbamate 39 (0.25g, 33%). IR ν max (neat) 645, 802, 1162, 1274, 1515, 1623, 1651, 1695, 3316cm À1 . 1 
General method (14a-f)
To a solution of appropriate acid (0.49mmol) in dichloromethane (10mL) at 0 C was added EDC (0.08g, 0.52mmol) and triethylamine (0.08mL, 0.57mmol). After 30 min, the primary amine liberated via trifluoroacetic acid treatment of 39 (100mg, 0.49mmol) was added to this solution. The reaction was allowed to reach room temperature and stirred for 24 h. The residual solvent was removed in vacuo, the residue extracted with saturated bicarbonate/DCM, and the crude organic residue purified by flash column chromatography (Pet. Ether:EtOAc 1:1) to afford the amide. 
